Category: Pharmaceuticals
Africa Pharmaceuticals
-
Morocco Pharmaceuticals & Healthcare Q4 2018
... treatments. Although the government'scommitment to improving healthcare via the expansion of health insurance coverage will be a significant factor for future medicinesales growth, we believe generics drugmakers will be the main beneficiaries as the state ... Read More
-
Tanzania Pharmaceuticals & Healthcare Q4 2018
... limited by low per capita spending on medicines andan underdeveloped healthcare sector. Whilst demand for medicine will increase over the long-term, driven by the country’s rapidlyexpanding population and high disease burden, we expect that Tanzania's ... Read More
-
Ethiopia Pharmaceuticals & Healthcare Q4 2018
... government is strongly committed to improvingthe operating environment to attract foreign investment, particularly from China, which combined with a budding manufacturingsector bodes well for foreign drugmaker appetite. Over the near-term, multinational drugmaker investment in the ... Read More
-
Angola Pharmaceuticals & Healthcare Q4 2018
... training doctors and nurses, weakening the pharmaceutical andhealthcare sectors. Angola’s new President, João Lourenço, has pledged to combat corruption, attract foreign investment andimprove healthcare services. However, we continue to view Angola as one of the ... Read More
-
Sudan and South Sudan Pharmaceuticals & Healthcare Q4 2018
... of commercial incentives limit multinational drugmaker interest in the market.Positive fundamentals in the form of a rising chronic disease burden and large population bode well for long-term opportunities,however, the elevated industry-and-operational risks will undermine any ... Read More
-
Cameroon Pharmaceuticals & Healthcare Q4 2018
... underpin rising spending on healthcare and pharmaceuticals.That said, low purchasing power and a poor operating environment will weigh on opportunities for drugmakers. Meanwhile, as themarket develops, local drug manufacturers will expand from a small base. Read More
-
Generics in South Africa
... of the leading players including key financial metrics and analysis of competitive pressures within the market. Synopsis Essential resource for top-line data and analysis covering the South Africa generics market. Includes market size data, textual ... Read More
-
Cote d'Ivoire Pharmaceuticals & Healthcare Q4 2018
... advantage, key factors such as limited access tomedicines and a lack of healthcare infrastructure will limit commercial opportunities. We hold a more positive long-term outlook onthe back of economic prosperity and the push for healthcare ... Read More
-
Kenya Pharmaceuticals & Healthcare Q4 2018
... ‘Big Four Agenda’ to 2022, providing upside risks to ourpharmaceuticals and healthcare forecasts. However, while this development highlights greater political will to improve healthcareaccess in Kenya, the target is highly ambitious over the coming five ... Read More
-
Egypt Pharmaceuticals & Healthcare Q4 2018
... to create difficult market conditions. Thecountry's designation as a ‘Watch List' country in PhRMA's 2018 submission highlights discriminatory market access policies, andlow levels of intellectual property protection as ongoing concerns for multinational drugmakers. Egypt's long-term ... Read More
-
Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Cancer Treatment Drugs Market 2018, Forecast to 2023
... it cans classification into Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), Hormonal Therapy and Others. Scope of the Report: This report focuses on the Cancer Treatment Drugs in global market, especially in North America, Europe and ... Read More
-
Zimbabwe Pharmaceuticals & Healthcare Q3 2018
... profile, wherea high prevalence of HIV/AIDS contributes to short life expectancy and low non-communicable disease burden. This profile willbenefit generic drugmakers operating in the country over the long-term, especially as the population grows. However, Zimbabwe ... Read More
-
Botswana Pharmaceuticals & Healthcare Q3 2018
... by a weakregulatory environment, small pensionable population and a highly ruralised community. Generic medicines will continue todominate the market, with patented drugmakers choosing to operate in larger markets in the region such as South African. Read More
-
Gabon Pharmaceuticals & Healthcare Q3 2018
... diseases will remain significant, we expect the increasein the incidence of non-communicable diseases to be the key driver of longer-term pharmaceutical market's trajectory. Commercialopportunities will mostly remain in the generic segment, given the rising role ... Read More
-
Sub-Saharan Africa Pharmaceuticals & Healthcare Q3 2018
... procedures, a lack of enforced patent laws, and ageneral lack of transparency that ensures the region lags behind others globally for revenue-earning opportunities. Despite this, theregion's pharmaceutical markets will continue to provide long-term opportunities for ... Read More
-
Tunisia Pharmaceuticals & Healthcare Q3 2018
... expect it to retain this position over the long term. Highlighting themarket's longer-term potential, some multinational drugmakers have shown their willingness to do business in the country, thoughthe majority choose to operate indirectly to minimise ... Read More
-
Ghana Pharmaceuticals & Healthcare Q3 2018
... the market, somewhat limiting high-value commercial opportunities. We believethat Ghana’s ambition of becoming the strategic hub for pharmaceutical investment in the ECOWAS region as a highly ambitioustarget, with Nigeria’s dominance as the primary medicine manufacturer ... Read More
-
Namibia Pharmaceuticals & Healthcare Q3 2018
Namibia Pharmaceuticals & Healthcare Q3 2018 BMI View: The small overall size of the market will continue to discourage more concerted efforts by multinationals to enter Read More
-
Mozambique Pharmaceuticals & Healthcare Q3 2018
... – and poor regulatory enforcement. Although agrowing population, high disease burden and some efforts by the government to improve overall healthcare will support demandfor generic medicines, albeit limited, Mozambique will remain one of the least ... Read More
-
Nigeria Pharmaceuticals & Healthcare Q3 2018
... in line with increasinggovernment support, although the benefits are unlikely to be realised over the near-term. The majority of multinational drugmakerswill continue to opt for an indirect presence as the business climate remains decidedly difficult ... Read More
-
Mauritius Pharmaceuticals & Healthcare Q3 2018
... Healthcare infrastructureexpansion and the rising burden of chronic diseases will ensure that demand for treatment remains high. Despite short-termeconomic headwinds, Mauritius’s long-term growth outlook is broadly positive, as the island is moving towards becoming atranshipment ... Read More
-
Pharmaceuticals in South Africa
... of the leading players including key financial metrics and analysis of competitive pressures within the market. Synopsis Essential resource for top-line data and analysis covering the South Africa pharmaceuticals market. Includes market size data, textual ... Read More
-
Angola Pharmaceuticals & Healthcare Report Q3 2018
... demographic, per capita spending on medicines will remainsignificantly low over our forecast period. However, overall growth of the market will be supported by a rapidly growing populationcoupled with small but steady improvements to healthcare access ... Read More
-
Zambia Pharmaceuticals & Healthcare Report Q3 2018
... However, few opportunities exist from the perspective ofmultinational companies, given factors such as the low purchasing power and the wide-spread presence of counterfeit medicines.On the other hand, authorities' support for the reduction of reliance on ... Read More
-
Free From in Egypt
... gluten or lactose, and attribute symptoms to other ailments. Moreover, even if consumers are aware that they have food allergies, it is often difficult for them to find free from products that meet their needs. ... Read More
Research Assistance
